Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8418-8424

  Cohen, Ezra E W ^a,b,c   Kane, Madeleine A ^d   List, Marcy A ^b   Brockstein, Bruce E ^e   Mehrotra, Bhoomi ^f   Huo, Dezheng ^c   Mauer, Ann M ^a,b   Pierce, Carolyn ^a   Dekker, Allison ^a   Vokes, Everett E ^a,b,c  

^a Section of Pediatric Hematology/Oncology   (United States)

^b University of Chicago   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; GEFITINIB; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; KERATOCONJUNCTIVITIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECURRENT CANCER; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; QUINAZOLINES; SALVAGE THERAPY; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28544432807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1247     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743-52.
3. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21: 1980-7.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-58.
6. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60.
7. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
8. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61:6500-10.
9. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
10. Ciardiello F, Caputo R, Borriello G, et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002;98:463-9.
11. Kishida O, Miyazaki Y, Murayama Y, et al. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 2005;55:393-403.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Cantarini MV, McFarquhar T, Smith RP, Bailey C, Marshall AL. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. Clin Ther 2004; 26:1630-6.
14. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
15. Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003;21:526-35.
16. Diggle PJ HP, Liang K-Y, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press: 2002.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. N Engl J Med 2005;353: 123-32.
18. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
19. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
20. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-82.
21. Cohen EEW LM, Martin LE, Harris PL, et al. The response of squamous cell carcinomas of the head and neck to tyrosine kinase inhibitors of the epidermal growth factor receptor is not associated with mutations in the receptor. Clin Cancer Res. In press 2005.
22. Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004;29:138-40.
23. Van Doom R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147:598-601.
24. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
25. Bruno RMR, Jones C, Lu JF, Winer E. Preliminary population pharmacokinetics (PPK) and exposure-safety (E-S) relationships of erlotinib HCL in patients with metastatic breast cancer (MBC). Vol. 22. ASCO Annual Meeting; 2003.
26. Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46-53.
27. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64: 9139-43.
28. Mutsaers AJMS, Ebos JML, Francia G, Loizos N, Hicklin DJ, Kerbel RS. Increased ligand as a biomarker to guide optimal dosing of targeted antibody drugs to receptor tyrosine kinases. 96th Annual Meeting of the American Association for Cancer Research, Anaheim, California; 2005.